

FROM PRESCRIPTION TO TREATMENT IN 4 STEPS.

When you are on SKYRIZI, you're a key player in the treatment process. The graphic below will help you better understand the important role you play.

► STEPS 1 AND 2 ARE FOR YOUR FIRST INJECTION



Your doctor writes your prescription and sends it to the specialty pharmacy (SPP).



Ask your doctor which SPP the prescription was sent to, and write down the name and phone number.

Your doctor schedules your injection appointment.



Your SPP receives the prescription from your doctor and contacts your insurance company.

Your insurance company validates your coverage and authorizes payment for SKYRIZI.



Expect a call from your SPP. Arrange for your co-pay and confirm where your SKYRIZI is being delivered.



3

YOUR SKYRIZI ARRIVES



SPP fills your prescription and delivers SKYRIZI to your home or your doctor's office.



If SKYRIZI is delivered to your home, keep it refrigerated until the day of your appointment or in-home injection. Or, if your medicine is being delivered to your doctor's office, call a few days in advance to confirm that it has arrived.



Go to your doctor's office to receive your injection or inject at home on your scheduled day.

Mark down the date of your next injection on your calendar or use the Skyrizi Complete App.



For any questions about preparing for your upcoming injection, call your **Skyrizi[®] COMPLETE** Nurse Ambassador* at **1.866.SKYZIRI** (1.866.759.7494).

*Nurse Ambassadors are provided by AbbVie and do not work under the direction of your health care professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.

Please see Use and Important Safety Information on next page.

Please see full Prescribing Information, including Medication Guide, at www.rxabbvie.com/pdf/skyrizi_pi.pdf and discuss with your doctor.

Skyrizi[®]
risankizumab-rzaa

USE AND IMPORTANT SAFETY INFORMATION

About SKYRIZI® (risankizumab-rzaa)¹

SKYRIZI Uses¹

SKYRIZI is a prescription medicine used to treat adults:

- with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).
- with active psoriatic arthritis (PsA).

Important Safety Information¹

What is the most important information I should know about SKYRIZI® (risankizumab-rzaa)?

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions:

- Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:
 - fainting, dizziness, feeling lightheaded (low blood pressure)
 - trouble breathing or throat tightness
 - chest tightness
 - swelling of your face, eyelids, lips, mouth, tongue, or throat
 - skin rash, hives
 - itching

Infections:

SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.

- Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
 - fever, sweats, or chills
 - cough
 - shortness of breath
 - blood in your mucus (phlegm)
 - muscle aches
 - warm, red, or painful skin or sores on your body different from your psoriasis
 - weight loss
 - diarrhea or stomach pain
 - burning when you urinate or urinating more often than normal

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI.

Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:

- have any of the conditions or symptoms listed in the section “What is the most important information I should know about SKYRIZI?”
- have an infection that does not go away or that keeps coming back.
- have TB or have been in close contact with someone with TB.
- have recently received or are scheduled to receive an immunization (vaccine). Medications that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine.
- are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SKYRIZI?

SKYRIZI may cause serious side effects. See “What is the most important information I should know about SKYRIZI?”

The most common side effects of SKYRIZI include upper respiratory infections, feeling tired, fungal skin infections, headache, and injection site reactions.

These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help.

Visit AbbVie.com/myAbbVieAssist to learn more.

Reference: 1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.

Please see full Prescribing Information, including Medication Guide, at www.rxabbvie.com/pdf/skyrizi_pi.pdf and discuss with your doctor.

abbvie

© 2022 AbbVie. All rights reserved.
SKYRIZI® and its design are registered
trademarks of AbbVie Biotechnology Ltd.
US-SKZD-220346 April 2022


Skyrizi[®]
risankizumab-rzaa